ライフサイエンスコーパス: smoking cessation

1 ressure control, cholesterol management, and smoking cessation).

2 ] control, cholesterol level management, and smoking cessation).

3 agonist of some nAChRs and has been used for smoking cessation.

4 m may represent a promising treatment to aid smoking cessation.

5 significantly elevated beyond 5 years after smoking cessation.

6 hol misuse, well-being, change in HbA1c, and smoking cessation.

7 but we do not see evidence for an effect on smoking cessation.

8 sibly to improved therapeutic treatments for smoking cessation.

9 rettes per day, and a willingness to attempt smoking cessation.

10 ) of alpha7 receptors, JNJ-39393406, may aid smoking cessation.

11 her be studied in a larger clinical trial of smoking cessation.

12 reduction, increasing physical activity, and smoking cessation.

13 tential methods and resources to assist with smoking cessation.

14 ic obstructive pulmonary disease, even after smoking cessation.

15 sk of EAC, although some evidence exists for smoking cessation.

16 loci for smoking initiation and 13 loci for smoking cessation.

17 ontributing to its ability to aid in tobacco smoking cessation.

18 ks of smoking, and counseling patients about smoking cessation.

19 tion if nurses are to be effective agents of smoking cessation.

20 ation and airway wall remodeling, even after smoking cessation.

21 altered methylation, with attenuation, after smoking cessation.

22 group received a leaflet with information on smoking cessation.

23 cial incentives increased long-term rates of smoking cessation.

24 the previous development of varenicline for smoking cessation.

25 hat, at many loci, persists many years after smoking cessation.

26 D prevention and tobacco cessation drugs for smoking cessation.

27 n-hospital following ACS, is efficacious for smoking cessation.

28 n reducing child TSE and increasing parental smoking cessation.

29 The primary endpoint was cigarette smoking cessation.

30 keletal muscle are most likely reversible by smoking cessation.

31 ddiction, smoking, cigarettes, nicotine, and smoking cessation.

32 four incentive programs or to usual care for smoking cessation.

33 esponse to nicotine patch or varenicline for smoking cessation.

34 cline is an effective pharmacotherapy to aid smoking cessation.

35 d by clinical guidelines recommending abrupt smoking cessation.

36 lution of epigenetic changes with time since smoking cessation.

37 g-related brain changes are reversible after smoking cessation.

38 [CI, 2.02 to 2.55]) were also effective for smoking cessation.

39 ly methylated, even more than 35 years after smoking cessation.

40 own regarding the underlying neurobiology of smoking cessation.

41 enicline's efficacy as a pharmacotherapy for smoking cessation.

42 rly and sustained antiretroviral therapy and smoking cessation.

43 o promote a healthy lifestyle, in particular smoking cessation.

44 Rs provide a promising novel drug target for smoking cessation.

45 individuals remained elevated >5 years after smoking cessation.

46 eing, change in haemoglobin A1c (HbA1c), and smoking cessation.

47 eight is a major factor that interferes with smoking cessation.

48 ily planning needs, reproductive health, and smoking cessation.

49 osylated hemoglobin (-0.92%; p < 0.001), and smoking cessation (20.2%; p = 0.002).

50 These findings reinforce the importance of smoking cessation advice in preconception and antenatal

51 ponse relationship exists and the time since smoking cessation affects methylation levels.

52 Smoking cessation after acute myocardial infarction (AMI

53 We conclude that varenicline as a smoking cessation agent differs from nicotine through tr

54 The smoking cessation agent varenicline, a partial agonist o

55 ttempts to reduce the risk of IF may include smoking cessation, aggressive control of hyperglycemia,

56 the effectiveness and safety of cystine as a smoking cessation aid in patients with tuberculosis in B

57 g Administration-approved antidepressant and smoking cessation aid, blocks dopamine and norepinephrin

58 e, popular antidepressant also marketed as a smoking cessation aid.

59 cigarettes (e-cigarettes) are the preferred smoking-cessation aid in the United States; however, the

60 use of preventable diseases; thus, effective smoking cessation aids are crucial for reducing the prev

61 The limited number of smoking cessation aids currently available are minimally

62 Despite efforts to produce suitable smoking cessation aids, addiction to nicotine continues

63 f nicotine and varenicline, two FDA-approved smoking cessation aids, during abstinence), on two well-

64 ts could serve as harm-reduction devices and smoking cessation aids.

65 chiatric and neurodegenerative disorders and smoking cessation aids.

66 n of substrates for the design of innovative smoking cessation aids.

67 re included informational resources and free smoking-cessation aids.

68 5]) and remained 8-fold higher 5 years after smoking cessation (aIRR, 8.69 [95% CI, 3.40-22.18]).

69 ets for improving lung function and possibly smoking cessation, although larger, tissue-specific data

70 iation between e-cigarette use and cigarette smoking cessation among adult cigarette smokers, irrespe

71 Odds of smoking cessation among smokers using e-cigarettes compa

72 armacotherapy interventions improve rates of smoking cessation among the general adult population, al

73 ed programmes of screening, vaccination, and smoking cessation, among other prevention strategies.

74 s mellitus, blood cholesterol, hypertension, smoking cessation and aspirin use.

75 ated into most public health guidelines (eg, smoking cessation and control of bodyweight and blood pr

76 Smoking cessation and control of diastolic blood pressur

77 was also evaluated according to duration of smoking cessation and cumulative (number of pack-years)

78 orporating both lifestyle changes, including smoking cessation and exercise, as well as optimal medic

79 ressed efficacy of electronic cigarettes for smoking cessation and found no benefit.

80 ote health initiatives in areas ranging from smoking cessation and healthy diet to organ transplantat

81 observed in former smokers for decades after smoking cessation and in current smokers with low cumula

82 of reduced-nicotine cigarettes to facilitate smoking cessation and on policy regarding regulation of

83 ing may be an effective way to increase male smoking cessation and reduce mother and newborn SHS expo

84 This inflammation may persist even after smoking cessation and responds variably to corticosteroi

85 he association between cigarette smoking and smoking cessation and the prevalence and incidence of to

86 inform genetic therapeutic interventions for smoking cessation and tobacco-related diseases.

87 bout and receive preventive measures such as smoking cessation and vaccination.

88 ogy-assisted interventions improved rates of smoking cessation and weight loss, respectively.

89 baseline and at 4, 8, 16, and 24-weeks after smoking-cessation and put onto Gene ST arrays.

90 recommended, starting with lifestyle advice, smoking cessation, and control of known cardiovascular r

91 Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer

92 e importance of smoking prevention and early smoking cessation, and indicate the need for public stat

93 terventions such as lowering blood pressure, smoking cessation, and lifestyle optimisation are common

94 ypical of never smokers within decades after smoking cessation, and sites remaining differentially me

95 l, lipid control, diabetic glycemic control, smoking cessation, and target body mass index by engagin

96 gnificantly increased within 3-9 years since smoking cessation, and the significant association persi

97 , to review current approaches to water pipe smoking cessation, and to offer guidance to healthcare p

98 Smoking behaviors, including amount smoked, smoking cessation, and tobacco-related diseases, are alt

99 he dynamics of methylation changes following smoking cessation are driven by a differential and site-

100 Although diet, exercise, and smoking cessation are first steps for patients with a pr

101 Weight loss and smoking cessation are often useful.

102 fected persons, but the clinical benefits of smoking cessation are unknown.

103 ettes per day, pack-years smoked, time since smoking cessation) as risk predictors.

104 ctiveness of TWH interventions for improving smoking cessation, as measured by self-reported 7-day ab

105 The primary endpoint was smoking cessation at 12 months ascertained via carbon mo

106 cline versus NRT and the primary outcome was smoking cessation at 2-years.

107 dividual-level behavioural interventions for smoking cessation at 6 months or longer of follow-up in

108 Behavioral interventions increased smoking cessation at 6 months or more (physician advice

109 condary endpoints were biologically verified smoking cessation at 6 months; number of cigarettes smok

110 ession profiling of individuals initiating a smoking-cessation attempt, we sought to characterize the

111 se for the initialization and maintenance of smoking cessation because of their ability to block the

112 ve pulmonary disease and a short duration of smoking cessation before LTx were at greatest risk of to

113 ic control and preventive measures including smoking cessation, blood pressure control, and lipid man

114 HIV, and reinforce preventive measures (eg, smoking cessation, blood pressure control, lipid managem

115 IV, and reinforce preventive measures (e.g., smoking cessation, blood pressure control, lipid managem

116 oking-related CMH usually resolves following smoking cessation but the longer its duration the greate

117 ffers an intriguing therapeutic approach for smoking cessation, but a reliably effective and immunolo

118 perceived stress may comprise a barrier for smoking cessation, but little is known about the associa

119 Smoking cessation by 10%-25% of HIV-infected smokers cou

120 incidence of quitting at 6 months shows that smoking cessation can be achieved, but the waning of thi

121 While smoking cessation can slow the damage in COPD, lung immu

122 ombined (n = 2183) was highest <1 year after smoking cessation compared to never smokers (aIRR, 1.66

123 Smoking cessation could potentially prevent more than 40

124 ACEI/ARB (OR: 2.6; 95% CI: 1.8 to 3.9), and smoking cessation counseling (OR: 4.4; 95% CI: 2.0 to 9.

125 ion, referral to cardiac rehabilitation, and smoking cessation counseling for patients with AMI.

126 RATIONALE: Smoking cessation counseling in conjunction with low-dos

127 Among current smokers with PAD, smoking cessation counseling or medication was used in 3

128 effectiveness of a medical (walking program, smoking cessation counseling, and medications) vs revasc

129 ho did not receive face-to-face or telephone smoking cessation counseling, large financial incentives

130 ceptor antagonists, use of beta-blocker, and smoking cessation counseling.

131 -analysis of 9 trials that measured parental smoking cessation demonstrated no overall intervention e

132 otine has practical applications relating to smoking cessation devices and alternative nicotine produ

133 ncing that is controlled by low doses of the smoking cessation drug varenicline.

134 Smoking cessation during nasal pneumococcal colonization

135 enuation was largely due to a higher rate of smoking cessation during the study period among men with

136 tcome expectancies support the importance of smoking cessation efforts in patients with orofacial pai

137 th screening, highlighting the importance of smoking cessation efforts in screening programs.

138 Deterring uptake of smoking and smoking cessation efforts should be prioritised to reduc

139 primary care, pulmonology, health behavior, smoking cessation, epidemiology, and disparities researc

140 ion levels of 119 genes were associated with smoking-cessation (FDR < 0.05, FC >=1.7) with a majority

141 This issue provides a clinical overview of smoking cessation, focusing on health consequences of sm

142 ients to quit and 25% less likely to arrange smoking cessation follow-up.

143 cline, begun in-hospital, is efficacious for smoking cessation following ACS.

144 bespoke intervention is a candidate model of smoking cessation for clinicians and policy makers to ad

145 ated risk persisted up to 30 years following smoking cessation for PAD and up to 20 years for CHD.

146 Most smoking cessation guidelines advise quitting abruptly.

147 Socioeconomic inequalities in smoking cessation have led to development of interventio

148 ealth successes, including HIV treatment and smoking cessation, have contributed to declining prematu

149 t that lung function decline normalises with smoking cessation; however, mechanistic studies suggest

150 asize cardiovascular disease prevention (eg, smoking cessation, hypertension control, lipid managemen

151 cant benefits of medication on likelihood of smoking cessation in 2 trials of bupropion at 26 weeks (

152 tiation, cigarettes per day, pack-years, and smoking cessation in a fixed effects meta-analysis of up

153 nd telephone counseling, are efficacious for smoking cessation in CVD patients.

154 termine the best strategies for facilitating smoking cessation in dental patients.

155 dentify and overcome barriers to integrating smoking cessation in lung cancer screening settings.

156 ess and safety of varenicline versus NRT for smoking cessation in people with neurodevelopmental diso

157 sk population and to determine the effect of smoking cessation in this genotype.Methods: We prospecti

158 ession alterations in response to short-term smoking-cessation in the nasal epithelium.

159 nAChR PAM compound for possible efficacy in smoking cessation, in smokers with or without schizophre

160 actors associated with greater benefits from smoking cessation included younger age, higher initial C

161 rease in the risk for the RP as the years of smoking cessation increased.

162 tients were randomly assigned to the bespoke smoking cessation intervention (n=265) or usual care (n=

163 The bespoke smoking cessation intervention consisted of behavioural

164 examined the effectiveness of a video-based smoking cessation intervention focusing on maternal and

165 This smoking cessation intervention for expectant fathers tha

166 In the smoking cessation intervention for severe mental illness

167 Mobile-phone-based smoking cessation intervention has been shown to increas

168 ts were randomly assigned (1:1) to a bespoke smoking cessation intervention or to usual care.

169 f a combined behavioural and pharmacological smoking cessation intervention targeted specifically at

170 d ratio [HR] 5.03, 4.98 to 5.08, P < 0.001), smoking cessation interventions (HR 3.20, 3.13 to 3.27,

171 Although the efficacy and safety of smoking cessation interventions are well established, th

172 als in tobacco control and expect to receive smoking cessation interventions during their hospital st

173 and safety of pharmacological and behavioral smoking cessation interventions in CVD patients via a me

174 g behaviours influence their engagement with smoking cessation interventions is needed.

175 l of nurses' engagement with the delivery of smoking cessation interventions requires attention if nu

176 g cancer screening setting of evidence-based smoking cessation interventions shown to be effective in

177 y outcomes, yet there is a lack of effective smoking cessation interventions targeted at expectant fa

178 unding the integration and implementation of smoking cessation interventions with LDCT lung cancer sc

179 ized tools for use in conducting research on smoking cessation interventions within the LDCT lung can

180 The best approach for integrating effective smoking cessation interventions within this setting is u

181 l units had higher expectations of receiving smoking cessation interventions.

182 l illness and the effectiveness of available smoking cessation interventions.

183 elp clinicians to develop effective tailored smoking cessation interventions.

184 after using the Gold Standard Programme for smoking cessation, investigation into novel therapeutic

185 Addressing smoking cessation is a critical component of comprehensi

186 Smoking cessation is an essential component of a high-qu

187 In type 2 diabetes, smoking cessation is associated with deterioration in gl

188 Smoking cessation is especially important for people who

189 Smoking cessation is important in patients with tubercul

190 Although this benefit of smoking cessation is not extended to those with >/=32 pa

191 A promising approach to smoking cessation is to remotely program variable transd

192 e of cardiovascular disease (CVD) risk after smoking cessation is unclear.

193 for smoking cessation.SIGNIFICANCE STATEMENT Smoking cessation leads the occurrence of physical and a

194 provide a promising target in the search for smoking cessation medication with novel mechanisms of ac

195 Smoking cessation medications are routinely used in heal

196 sed about the neuropsychiatric safety of the smoking cessation medications varenicline and bupropion.

197 e and/or immunosuppressive agents as well as smoking cessation might prevent conversion to GMG.

198 kinetics of gene-expression alterations upon smoking-cessation might delineate distinct biological pr

199 based programmes that promote weight loss or smoking cessation need to be more accessible for these p

200 In a randomized controlled trial of smoking cessation nested within the original prospective

201 act of nicotine, including nicotine found in smoking-cessation nicotine-replacement therapies, may ha

202 ral modification, such as dietary changes or smoking cessation, not only reduces stroke risk, but als

203 Our results provide a new paradigm for how smoking cessation occurs and suggest how more effective

204 prediction shows that the genetic effects of smoking cessation on body weight vary from different pop

205 SZ registry data to determine the effect of smoking cessation on spirometry decline (n = 60) and pla

206 cumulative smoking exposure and duration of smoking cessation on the recurrence of periodontitis.

207 risks of smoking, and discuss with patients smoking cessation options.

208 ess to quit smoking, and most do not discuss smoking cessation options.

209 ful in promoting healthier behaviors such as smoking cessation or in aiding persons with a family his

210 of Hb-IP nAChRs, either volitionally during smoking cessation or inadvertently via receptor desensit

211 ake of targeted preventive services, such as smoking cessation or relevant immunizations; and the pos

212 ts by socioeconomic position, did not report smoking cessation outcomes from 6 months or longer after

213 ring early withdrawal may be associated with smoking cessation outcomes.

214 ight be necessary to achieve equity-positive smoking cessation outcomes.

215 tween diabetic kidney disease and failure at smoking cessation (P=1.1x10(-4)).

216 Treatment consists primarily of alcohol and smoking cessation, pain control, replacement of pancreat

217 Secondary outcomes of interest were parental smoking cessation, parental smoking reduction, and mater

218 controlled trials evaluating the efficacy of smoking cessation pharmacotherapies and behavioral thera

219 andomized to one of three 12-week open-label smoking cessation pharmacotherapy groups: (1) nicotine p

220 us to optimise the selection and efficacy of smoking cessation pharmacotherapy.

221 udies were included if they reported nurses' smoking cessation practices in relation to their persona

222 Proportions of nurses' smoking status and smoking cessation practices were pooled across studies u

223 to have a negative impact in the delivery of smoking cessation practices.

224 nurses is associated with their professional smoking cessation practices.

225 nurses is associated with their professional smoking cessation practices.

226 of behavioural support from a mental health smoking cessation practitioner and pharmacological aids

227 5,314 people aged 18 and above with eligible smoking cessation prescriptions in the effectiveness ana

228 An adjunct smoking cessation program has the potential to improve o

229 An adjunct smoking cessation program improving the quit rate by 22.

230 The effectiveness and safety of a smoking cessation programme designed particularly for pe

231 Some behavioural interventions (eg, smoking cessation programmes), although beneficial overa

232 Smoking cessation programs are still needed, particularl

233 includes counseling and pharmacotherapy for smoking cessation, pulmonary rehabilitation, treatment o

234 d with behavioral counseling still has a low smoking cessation rate of 25%.

235 ompared with placebo significantly increased smoking cessation rates at the end of treatment, and als

236 arge financial incentives improved long-term smoking cessation rates in low-income smokers, in a gene

237 large financial incentives enhance long-term smoking cessation rates outside clinical or workplace se

238 status (slow/normal metabolism) may improve smoking cessation rates.

239 ing smokers with spirometry results improves smoking cessation rates.

240 sation occurs and suggest how more effective smoking cessation reagents can be designed.

241 Electronic cigarettes (e-cigarettes) for smoking cessation remain controversial.

242 Symptom prevalence following smoking cessation returned to levels seen among never-sm

243 was comparable, except for a higher rate of smoking cessation screening and intervention (adjusted r

244 slation (n=35), tobacco taxation (n=11), and smoking cessation services (n=3).

245 Systematically providing smoking cessation services in hospitals may have a relev

246 investigate optimal approaches for providing smoking cessation services in the dental setting.

247 re participants were offered access to local smoking cessation services not specifically designed for

248 oke but typically do not access conventional smoking cessation services, contributing to widening hea

249 ividuals assigned to usual care accessed NHS smoking cessation services.

250 propriate, referral to weight management and smoking cessation services.

251 l illness have not historically engaged with smoking cessation services.

252 % of MIs among HIV-infected individuals, and smoking cessation should be a primary focus in modern HI

253 on the benefits and harms of screening, and smoking cessation should be offered to all current smoke

254 tified in the postoperative period, although smoking cessation should be strongly encouraged given th

255 Smoking cessation should become a priority in HIV treatm

256 Rgamma may offer an interesting strategy for smoking cessation.SIGNIFICANCE STATEMENT Smoking cessati

257 s via primary care after discussion with the smoking cessation specialist.

258 Smoking cessation strategies should be implemented, espe

259 ontrol group) or usual care plus the bespoke smoking cessation strategy (intervention group).

260 Participants engaged well with the bespoke smoking cessation strategy, but no individuals assigned

261 net effect of radiotherapy on mortality, but smoking cessation substantially reduces radiotherapy ris

262 hronic inflammation that persists even after smoking cessation, suggesting that a failure to resolve

263 genes remained elevated up to 30 years after smoking cessation, suggesting that the molecular consequ

264 se that smoke-free psychiatric units provide smoking cessation support on patient admission to the ho

265 in tobacco cessation (75.3%), should provide smoking cessation support to patients (83.0%), and that

266 n example and not smoke" and "should provide smoking cessation support"; (ii) hospitals "should provi

267 nd disease, as well as assists in optimizing smoking cessation support, which in turn will reduce the

268 show a higher risk in people 3-5 years after smoking cessation than in continuing smokers.

269 E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy, whe

270 ed the evidence on interventions for tobacco smoking cessation that are relevant to primary care (beh

271 After >15 years of smoking cessation, the risk of HF and death for most for

272 s entailed rewards of approximately $800 for smoking cessation; the others entailed refundable deposi

273 Smoking cessation therapeutics are only marginally effec

274 BAergic VTA neurons as molecular targets for smoking cessation therapeutics.

275 d to remote counseling apps for personalized smoking cessation therapy.

276 evention efforts should continue to focus on smoking cessation, these prospective findings support th

277 garettes) have been proposed as an effective smoking cessation tool.

278 ive to traditional cigarettes and a possible smoking cessation tool.

279 thdrawal may inform the development of novel smoking cessation treatments and reduce the harm caused

280 ion support"; (ii) hospitals "should provide smoking cessation treatments" and are "role model organi

281 izers may benefit from adjunctive behavioral smoking cessation treatments, such as cue exposure thera

282 d with that of nicotine products approved as smoking-cessation treatments.

283 of smoking-induced epigenetic changes after smoking cessation, using genome-wide methylation profile

284 Whether this health benefit of smoking cessation varies by amount and duration of prior

285 Among heavy smokers, smoking cessation was associated with significantly lowe

286 Smoking cessation was consistently associated with a red

287 A longer period of smoking cessation was consistently related to lower risk

288 Smoking cessation was highest among individuals who rece

289 patients admitted to general hospitals where smoking cessation was not given as part of their portfol

290 ference of 85 cm [men] or 80 cm [women], and smoking cessation) was associated with a one-third reduc

291 To better understand smoking cessation, we examined the actions of vareniclin

292 to receive either booklets plus access to a smoking cessation website (control group, n = 404), or t

293 ndividuals with diverse expertise related to smoking cessation were empaneled to prioritize questions

294 tive smoking exposure and shorter time since smoking cessation were significantly associated with the

295 Genes down-regulated by 4- and 8-weeks post-smoking-cessation were involved in xenobiotic metabolism

296 counseling (exercise or diet counseling and smoking cessation) were evaluated.

297 een behavioral interventions and controls in smoking cessation when trials were restricted to smokers

298 viours (active smoking, passive smoking, and smoking cessation) with risk of type 2 diabetes.

299 on practitioner and pharmacological aids for smoking cessation, with adaptations for people with seve

300 ning (MT) has shown preliminary efficacy for smoking cessation, yet its neurobiological target remain